Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carboplatin + irinotecan versus carboplatin + etoposide in elderly extensive-stage small-cell lung cancer
jRCTs031180193Phase 3Completed
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Feb 2014
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in small cell lung cancer (SCLC) comparing Carboplatin + etoposide with Carboplatin + irinotecan (2 arms). Primary endpoints: Overall survival and Response rate of carboplatin + irinotecan arm. Started Feb 2014; status: completed.
02
Drugs
carboplatinirinotecanetoposide
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on jRCTs031180193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180193.